Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Christian Vogelberg (Dresden, Germany), Christian Vogelberg, Stanley J. Szefler, Eckard Hamelmann, Attilio Boner, Petra Moroni-Zentgraf, Michael Engel, Georges El Azzi, Helen Finnigan, Mark Vandewalker. Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma. Eur Respir J 2016; 48: Suppl. 60, 1251

Member's Comments

No comment yet.

Related content which might interest you: Once-daily tiotropium Respimat® add-on therapy improves PEF in participants aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Tiotropium Respimat® add-on therapy in children with symptomatic asthma Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Safety of tiotropium in pre-school children with symptomatic persistent asthma Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016 LATE-BREAKING ABSTRACT: Safety and tolerability of once-daily tiotropium Respimat® add-on therapy in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016 LATE-BREAKING ABSTRACT: Once-daily tiotropium Respimat® add-on therapy improves lung function in children with moderate symptomatic asthma Source: International Congress 2016 – Living with asthma around the globe Year: 2016 Economic evaluation of eformoterol compared with salmeterol in children aged 6-17 years with symptomatic asthma in the UK: cost-effectiveness results of the FACT study Source: Eur Respir J 2001; 18: Suppl. 33, 122s Year: 2001 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy and safety of once-daily (OD) fluticasone furoate (FF) in adults and adolescents with moderate-to-severe persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5 Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Efficacy of tiotropium Respimat® in adults with moderate asthma, by baseline LTRA use Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Pharmacokinetics of tiotropium in asthma patients from three paediatric clinical trials Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Efficacy and safety of once-daily (OD) fluticasone furoate (FF) 50mcg over 24 weeks in adults and adolescents with persistent asthma Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 The add-on effect of tiotropium bromide to ICS/LABA combination inhaler for the patients with severe uncontrolled asthma Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 E-monitoring of asthma therapy to improve compliance in children (E-MATIC) Source: International Congress 2015 – Paediatric asthma and allergy: e-health in management Year: 2015 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Metered-dose inhaler albuterol: Evaluation of efficacy and safety of increasing doses in children with acute wheezing Source: International Congress 2014 – Paediatric asthma: lung function testing and more Year: 2014